133 related articles for article (PubMed ID: 8701927)
21. Endometrial hyperplasia/adenocarcinoma. a conventional approach.
Mazur MT
Ann Diagn Pathol; 2005 Jun; 9(3):174-81. PubMed ID: 15944963
[TBL] [Abstract][Full Text] [Related]
22. [A comparative morphometric and DNA content study of endometrial hyperplasia and adenocarcinoma].
Zhou XR; Du XG
Zhonghua Fu Chan Ke Za Zhi; 1992 Sep; 27(5):278-80, 316. PubMed ID: 1298588
[TBL] [Abstract][Full Text] [Related]
23. Prognostic importance of hyperplasia and atypia in endometriosis.
Seidman JD
Int J Gynecol Pathol; 1996 Jan; 15(1):1-9. PubMed ID: 8852439
[TBL] [Abstract][Full Text] [Related]
24. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia.
Sun H; Enomoto T; Fujita M; Wada H; Yoshino K; Ozaki K; Nakamura T; Murata Y
Am J Clin Pathol; 2001 Jan; 115(1):32-8. PubMed ID: 11190805
[TBL] [Abstract][Full Text] [Related]
25. [Diagnosis of endometrial cancer by DNA cytophotometry].
Dietl J; Hedderich J; Sprenger E
Geburtshilfe Frauenheilkd; 1986 Nov; 46(11):796-9. PubMed ID: 3803873
[TBL] [Abstract][Full Text] [Related]
26. The endometrial hyperplasias and their relationship to endometrial neoplasia.
Fox H; Buckley CH
Histopathology; 1982 Sep; 6(5):493-510. PubMed ID: 6754573
[TBL] [Abstract][Full Text] [Related]
27. Differences in DNA content and proliferation rate between adenocarcinomas of the uterine cervix and corpus.
Strang P; Stendahl U; Lindgren A; Sténson S
In Vivo; 1987; 1(2):109-12. PubMed ID: 2979770
[TBL] [Abstract][Full Text] [Related]
28. Cellular features of endometrial hyperplasia and well differentiated adenocarcinoma using the Endocyte sampler: Diagnostic criteria based on the cytoarchitecture of tissue fragments.
Norimatsu Y; Shimizu K; Kobayashi TK; Moriya T; Tsukayama C; Miyake Y; Ohno E
Cancer; 2006 Apr; 108(2):77-85. PubMed ID: 16463402
[TBL] [Abstract][Full Text] [Related]
29. Flow-cytometric analysis of nuclear DNA content in endometrial adenocarcinoma. Atypical mitoses are associated with DNA aneuploidy.
Genest DR; Sheets E; Lage JM
Am J Clin Pathol; 1994 Sep; 102(3):341-8. PubMed ID: 8085558
[TBL] [Abstract][Full Text] [Related]
30. Laminin immunostaining in hyperplastic, dysplastic, and neoplastic lesions of the endometrium and uterine cervix.
Vogel HP; Mendelsohn G
Obstet Gynecol; 1987 May; 69(5):794-9. PubMed ID: 2437505
[TBL] [Abstract][Full Text] [Related]
31. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients.
Kurman RJ; Kaminski PF; Norris HJ
Cancer; 1985 Jul; 56(2):403-12. PubMed ID: 4005805
[TBL] [Abstract][Full Text] [Related]
32. GLUT-1 is preferentially expressed in atypical endometrial hyperplasia and endometrial adenocarcinoma.
Ashton-Sager A; Paulino AF; Afify AM
Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):187-92. PubMed ID: 16785788
[TBL] [Abstract][Full Text] [Related]
33. Flow cytometry of normal, hyperplastic, and malignant human endometrium. A study of ploidy and proliferative indices including comparison with in vitro S-phase labeling.
Thornton JG; Quirke P; Wells M
Am J Obstet Gynecol; 1989 Aug; 161(2):487-92. PubMed ID: 2475021
[TBL] [Abstract][Full Text] [Related]
34. Genetic imbalances in endometrial hyperplasia and endometrioid carcinoma detected by comparative genomic hybridization.
Muslumanoglu HM; Oner U; Ozalp S; Acikalin MF; Yalcin OT; Ozdemir M; Artan S
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):107-14. PubMed ID: 15866096
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometry as a prognostic method for the identification of adenomatous hyperplasia at risk of developing endometrial carcinoma.
Lindahl B; Willén R
Anticancer Res; 1998; 18(6B):4611-2. PubMed ID: 9891527
[TBL] [Abstract][Full Text] [Related]
36. Detection of PTEN immunoreactivity in endometrial hyperplasia and adenocarcinoma.
Tantbirojn P; Triratanachat S; Trivijitsilp P; Niruthisard S
J Med Assoc Thai; 2008 Aug; 91(8):1161-5. PubMed ID: 18788685
[TBL] [Abstract][Full Text] [Related]
37. Microcarcinoma of the endometrium: a mapping study with special reference to cytologic atypia in the endometrium.
Hachisuga T; Sugimori H; Kaku T; Tsuneyoshi M
Jpn J Clin Oncol; 1992 Dec; 22(6):400-5. PubMed ID: 1291756
[TBL] [Abstract][Full Text] [Related]
38. The cytodynamics of endometrial hyperplasia and carcinoma. A review.
Ferenczy A; Gelfand MM; Tzipris F
Ann Pathol; 1983 Sep; 3(3):189-201. PubMed ID: 6354201
[TBL] [Abstract][Full Text] [Related]
39. Flow cytometric cell cycle kinetics and quantitative measurement of c-erbB-2 and mutant p53 proteins in normal, hyperplastic, and malignant endometrial biopsies.
Eissa S; Abu Saada M; el-Sharkawy T
Clin Biochem; 1997 Apr; 30(3):209-14. PubMed ID: 9167896
[TBL] [Abstract][Full Text] [Related]
40. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
